“`html
Summary: Financial Impact of Bevacizumab Treatment for Juvenile-onset Recurrent Respiratory Papillomatosis (JoRRP)
Background: JoRRP is a rare and costly condition linked to human papillomavirus, requiring frequent surgical debridement as the standard care. Systemic bevacizumab has shown promising results as an adjunctive therapy.
Study Objective:
To assess the financial implications of using systemic bevacizumab for JoRRP compared to surgical care alone.
Methodology:
- Five patients receiving bevacizumab for JoRRP were studied at a single institution.
- Healthcare spending data was collected from electronic medical records.
- Sensitivity analysis was conducted to account for spending variations and treatment frequency.
Key Findings:
- Prior to bevacizumab treatment, patients underwent an average of 4.2 surgical treatments per year, compared to 1.1 after initiating bevacizumab.
- Mean payment per debridement was $3198, with a mean annual surgical payment of $17,966 before bevacizumab treatment.
- Mean payment for a single bevacizumab infusion visit was $6508.
- After bevacizumab initiation, mean total annual spending on surgical and bevacizumab treatment was $83,951.
Conclusion:
Healthcare spending after bevacizumab treatment initiation is comparable to spending on surgery alone for JoRRP in patients with severe disease.
“`
